OAM
AMLX icon

Oberweis Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Oberweis Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-170,000
Closed -$3.11M – 195
2023
Q3 		$3.11M Buy
170,000
+85,000
+100% +$1.8M 0.33% 118
2023
Q2 		$1.83M Buy
85,000
+24,695
+41% +$667K 0.22% 136
2023
Q1 		$1.77M Buy
+60,305
New +$2.1M 0.27% 123

Other funds holding AMLX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oberweis Asset Management's AMLX Position: Q4 2023 in Review

Oberweis Asset Management sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2023, closing a stake of 170,000 shares — an estimated $3.11M sold.

Oberweis Asset Management first reported a position in AMLX in Q1 2023 and held it in 3 quarters. The position peaked at $3.11M in Q3 2023. 178 funds tracked by Wall St. Rank hold AMLX as of Q4 2023.

  • Oberweis Asset Management reported no remaining Amylyx Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Oberweis Asset Management sold 170,000 Amylyx Pharmaceuticals shares in Q4 2023, an estimated $3.11M.
  • Oberweis Asset Management first reported a position in Amylyx Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • Oberweis Asset Management's Amylyx Pharmaceuticals position peaked at $3.11M in Q3 2023.
  • 178 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2023.

Based on Oberweis Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.